Biotime Inc (NYSEAMERICAN:BTX) Shorts Decreased by 0.78% After Short Covering

Lineage Cell Therapeutics, Inc. (NYSEAMERICAN:BTX) Logo

Investors sentiment increased to 2 in Q1 2019. Its up 0.81, from 1.19 in 2018Q4. It is positive, as 13 investors sold Lineage Cell Therapeutics, Inc. shares while 15 reduced holdings. 22 funds opened positions while 34 raised stakes. 60.97 million shares or 15.50% more from 52.79 million shares in 2018Q4 were reported.
Connor Clark & Lunn Inv Management Limited owns 14,000 shares or 0% of their US portfolio. Jefferies Group accumulated 87,189 shares or 0% of the stock. Sequoia Fin Advsrs Ltd Liability, Ohio-based fund reported 68,735 shares. Morgan Stanley owns 65,463 shares for 0% of their portfolio. Tiaa Cref Inv Lc stated it has 552,246 shares or 0% of all its holdings. Moors And Cabot Inc has invested 0.01% in Lineage Cell Therapeutics, Inc. (NYSEAMERICAN:BTX). Jane Street Grp Ltd Limited Liability Company owns 180,387 shares or 0% of their US portfolio. The Pennsylvania-based Glenmede Trust Na has invested 0% in Lineage Cell Therapeutics, Inc. (NYSEAMERICAN:BTX). Principal Financial Grp Incorporated Inc reported 0% in Lineage Cell Therapeutics, Inc. (NYSEAMERICAN:BTX). Moreover, Bankshares Of Montreal Can has 0% invested in Lineage Cell Therapeutics, Inc. (NYSEAMERICAN:BTX). Bnp Paribas Arbitrage Sa invested 0% of its portfolio in Lineage Cell Therapeutics, Inc. (NYSEAMERICAN:BTX). Citadel Advsrs Limited Co owns 94,147 shares for 0% of their portfolio. First Manhattan Co holds 0% of its portfolio in Lineage Cell Therapeutics, Inc. (NYSEAMERICAN:BTX) for 94 shares. Geode Capital Management invested in 1.45 million shares or 0% of the stock. Prudential Financial reported 17,332 shares.

The stock of Biotime Inc (NYSEAMERICAN:BTX) registered a decrease of 0.78% in short interest. BTX’s total short interest was 10.02M shares in August as published by FINRA. Its down 0.78% from 10.10M shares, reported previously. With 509,800 shares average volume, it will take short sellers 20 days to cover their BTX’s short positions.

The stock decreased 7.08% or $0.0701 during the last trading session, reaching $0.9199. About 694,268 shares traded or 48.20% up from the average. Lineage Cell Therapeutics, Inc. (NYSEAMERICAN:BTX) has declined 40.74% since August 14, 2018 and is downtrending. It has underperformed by 40.74% the S&P500.

BioTime, Inc., a clinical-stage biotechnology company, focuses on developing and commercializing products addressing degenerative diseases based on pluripotent stem cells and HyStem cell/drug delivery platform technologies. The company has market cap of $137.66 million. The Company’s product candidates include Renevia, a facial aesthetics product that is in pivotal clinical trial for the treatment of HIV related facial lipoatrophy; OpRegen, which is in Phase I/IIa clinical trial for the treatment of the dry form of age-related macular degeneration; HyStem-BDNF, a preclinical development program for the delivery of recombinant human brain-derived neurotrophic factor directly into the stroke cavity of patients for aiding in tissue repair and functional recovery; and ReGlyde that is in preclinical development as a device for viscosupplementation and a combination product for drug delivery in osteoarthritis. It has a 3.97 P/E ratio. The firm also develops AST-OPC1, a therapy derived from pluripotent stem cells that is in a Phase I/IIa clinical trial for spinal cord injuries; AST-VAC1, a patient-specific cancer immunotherapy that is in Phase II clinical trial for acute myeloid leukemia; and AST-VAC2, a non-patient specific cancer immunotherapy, which is in Phase I/IIa clinical trial to treat non-small cell lung cancer.

More notable recent Lineage Cell Therapeutics, Inc. (NYSEAMERICAN:BTX) news were published by: Globenewswire.com which released: “BioTime Enters Into Exclusive Agreement With Orbit Biomedical Ltd. to Access Innovative Device for the Sub-Retinal Delivery of OpRegenĀ® Cells for the Treatment of Dry-AMD – GlobeNewswire” on January 07, 2019, also Businesswire.com with their article: “BioTime and Asterias Biotherapeutics Enter Into Definitive Merger Agreement to Create Leading Cell Therapy Company – Business Wire” published on November 08, 2018, Businesswire.com published: “BioTime to Report Second Quarter 2019 Financial Results and Provide Business Update on August 8, 2019 – Business Wire” on August 01, 2019. More interesting news about Lineage Cell Therapeutics, Inc. (NYSEAMERICAN:BTX) were released by: Businesswire.com and their article: “AgeX Therapeutics, Inc. Shares Commence Trading on the NYSE American – Business Wire” published on November 29, 2018 as well as Globenewswire.com‘s news article titled: “BioTime to Present New Data From OpRegenĀ® and Vision Restoration Programs at the Association for Research in Vision and Ophthalmology Annual Meeting (ARVO 2019) – GlobeNewswire” with publication date: February 26, 2019.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.